Middle Eastern markets like Jordan and the United Arab Emirates appear to have become the frontrunners among non-ICH (International Council for Harmonisation) countries in introducing regulatory pathways that improve access to medicines. Through risk-stratification and relying on regulatory reviews by major agencies, Middle Eastern regulators are freeing up resources to tackle other problems, while also making their markets more attractive to investors.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?